Base to Base biotech podcast 24: Dissecting the US cuts to mRNA vaccine projects and Herantis takes on Parkinson’s disease

This week, we look at Herantis Pharma's work on Parkinson's disease, with the company's CEO, Antti Vuolanto, and we have an in-depth look at the recent cuts to mRNA vaccine projects, with Jean Peccoud, GenoFAB founder and professor at Colorado State University.

Interview times:

03:22 Herantis

16:28 mRNA cuts

Cuts to mRNA vaccine projects

The U.S. Department of Health and Human Services (HHS) recently announced a major shift in its vaccine development priorities, initiating a “co‑ordinated wind‑down” of mRNA vaccine projects under the Biomedical Advanced Research and Development Authority (BARDA). The move cancels or scales back 22 contracts worth nearly $500m, affecting research partnerships with universities, biotech firms, and major pharmaceutical companies.

The cuts have spa ...